Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBITDA Margin (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EBITDA Margin for 12 consecutive years, with 66325.58% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 10446505.0% year-over-year to 66325.58%, compared with a TTM value of 1840.55% through Dec 2025, down 86455.0%, and an annual FY2025 reading of 24754.14%, down 2377813.0% over the prior year.
  • EBITDA Margin was 66325.58% for Q4 2025 at Abvc Biopharma, up from 256.2% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 66325.58% in Q4 2025 and bottomed at 239206.22% in Q1 2024.
  • Average EBITDA Margin over 5 years is 15358.86%, with a median of 1113.98% recorded in 2024.
  • The sharpest move saw EBITDA Margin plummeted -23780718bps in 2024, then skyrocketed 23956525bps in 2025.
  • Year by year, EBITDA Margin stood at 22158.37% in 2021, then tumbled by -103bps to 757.2% in 2022, then plummeted by -2255bps to 17832.06% in 2023, then crashed by -114bps to 38139.47% in 2024, then skyrocketed by 274bps to 66325.58% in 2025.
  • Business Quant data shows EBITDA Margin for ABVC at 66325.58% in Q4 2025, 256.2% in Q3 2025, and 1713.42% in Q2 2025.